Change from original

Terms/Details (Date)

AltaRex Corp. (Canada; TSE:AXO)

United Therapeutics Corp. (UTHR)

Expanded agreement for the territory granted to United under an existing agreement to include Germany

The agreement grants United the right to certain AltaRex products including Ova- Rex, BrevaRex, ProstaRex and GivaRex; United made an initial payment and agreed on milestone payments for the Germany license; it also agreed to the same royalty payment structure in Germany as the U.S. and other countries (8/12)

CV Therapeutics Inc. (CVTX)

Innovex Inc. (INVX)

Renegotiated agreement returning all rights associated with the chronic angina candidate Ranexa to CV Therapeutics

CV Therapeutics has agreed to issue Innovex warrants for 200,000 shares; the companies signed the original marketing and sales deal in 1999; the companies will retain a commercialization service relationship and Innovex will become a preferred provider of pharmaceutical services for CV Therapeutics (7/11)

Epimmune Inc. (EPMN)

Immuno Designed Molecules SA* (France)

Exercised option to a non-exclusive license tocertain cancer epitopes for use in IDM's ex vivo cell therapy program

Epimmune received a license fee in connection with IDM exercising the option and is entitled to receive pre-commercialization milestones and royalties on product sales; the territory is worldwide except for Japan (7/8)

ICN Pharmaceuticals Inc. (NYSE:ICN)

Senetek plc (SNTK)

Expanded licensing agreement for ICN's Kinerase product line

The new license covers kinetin-containing products in North America, Europe and Australia; the expanded contract adds five products to the Kinerase line, including new serum and cream formulations with stabilized vitamin C (8/13)

Seattle Genetics Inc. (SGEN)

Genencor International Inc. (GCOR)

Extended and modified collaboration for a non- exclusive license to Seattle Genetics' antibody-directed enzyme prodrug therapy technology for use with multiple targets

The agreement is extended for two more years; Genencor will co-fund a portion of Seattle Genetics' prodrug program in support of Genencor's drug discovery efforts (7/29)


# The information in the chart does not cover agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange.